{ "model": { "rank": 8786, "code": "thing-q264118", "model_id": "vr.tr.acute-myeloid-leukemia", "name": "acute myeloid leukemia", "purpose": "Let an agent explain acute myeloid leukaemia and its subtypes, relay diagnosis, classification, treatment and prognosis from haematology guidelines in general terms, route people with symptoms or a diagnosis to clinicians, and distinguish AML from acute lymphoblastic leukaemia, chronic myeloid leukaemia and myelodysplastic syndromes.", "family": "Thing Registry", "category": "Information and virtual systems", "status": "research-draft", "kind": "thing", "plane": "INF", "domain": "INF.KNW", "industry": "", "version": "", "url": "/models/thing/q264118/", "tier": 2, "score": 49, "payload": { "layer": "wikidata", "aliases": [ "Acute myeloid dendritic cell leukemia", "inherited acute myeloid leukemia", "acute monocytic leukemia", "core binding factor acute myeloid leukemia", "Acute myeloblastic leukemia", "acute myeloid leukemia with BCR-ABL1", "erythremia", "acute erythroid leukemia", "acute eosinophilic leukemia", "Acute panmyelosis with myelofibrosis", "adult acute myeloid leukemia", "acute myeloid leukemia with myelodysplasia-related changes", "therapy-related acute myeloid leukemia", "mixed phenotype acute leukemia", "acute myeloid leukemia with 11q23 abnormalities", "unclassified acute myeloid leukemia", "acute myeloid leukemia with multilineage dysplasia", "acute myeloid leukemia with recurrent genetic anomaly", "acute promyelocytic leukemia", "adult acute monocytic leukemia", "childhood acute monocytic leukemia", "Minimally differentiated acute myeloblastic leukemia", "pure erythroid leukemia", "acute erythremia and erythroleukemia", "acute erythroleukemia, familial", "bilineal acute myeloid leukemia", "adult pure erythroid leukemia" ], "aliasCount": 27, "merged": 27, "knownIn": 49, "facets": null, "markers": [], "lexicalClass": "", "senseRank": null, "alsoRegisteredAs": null, "source": { "dataset": "wikidata", "item": "Q264118", "url": "https://www.wikidata.org/wiki/Q264118", "license": "CC0 1.0" } }, "research": { "vercy": "1.0-draft", "publication": { "status": "research-draft", "adjudicationStatus": "unreviewed", "publishableCanonical": false, "generatedAt": "2026-09-13T13:26:56Z", "providers": [ "Claude" ], "breadth": "written by Claude from model knowledge without web access - no source was read, every claim is a lead to verify", "pass": 2, "wave": 4, "engine": "claude" }, "metaModel": { "id": "THING-Q264118", "registryId": "vr.tr.acute-myeloid-leukemia", "name": "acute myeloid leukemia", "version": "0.2.0-wave.4", "entryKind": "thing", "family": "Thing Registry", "domain": [ "INF.KNW" ], "status": "research-draft" }, "canonicalUrl": "https://ver.cy/models/thing/q264118/", "model": { "registry_id": "vr.tr.acute-myeloid-leukemia", "name": "acute myeloid leukemia", "purpose": "Let an agent explain acute myeloid leukaemia and its subtypes, relay diagnosis, classification, treatment and prognosis from haematology guidelines in general terms, route people with symptoms or a diagnosis to clinicians, and distinguish AML from acute lymphoblastic leukaemia, chronic myeloid leukaemia and myelodysplastic syndromes.", "definition": "A cancer of the blood and bone marrow in which immature myeloid cells proliferate rapidly, classified by genetics and morphology into subtypes such as acute myeloblastic and acute monocytic leukaemia, core binding factor leukaemia with favourable genetics, cases with BCR-ABL1 and rare inherited predispositions, and occurring mainly in adults with rising incidence with age; it is treated with intensive chemotherapy, targeted drugs and stem cell transplantation, and suspected cases need urgent haematology referral.", "what_it_is_for": "Not applicable; a disease.", "affordances": [ "explain subtypes", "relay diagnosis and treatment", "route to clinicians", "distinguish related diseases" ], "distinguishing_features": [ "Myeloid lineage", "Rapid course", "Genetic classification", "Intensive treatment" ], "appearance": "Not a visible object; fatigue, infections and bleeding from marrow failure.", "visual_identification": [ "Rapid cancer of immature myeloid cells", "Acute myeloblastic, acute monocytic, core binding factor, BCR-ABL1 positive, inherited AML", "ALL involves lymphoid cells; CML is chronic; MDS is a precursor state" ], "physical_properties": [ { "quantity": "new cases, US", "typical_range": "about 20000", "unit": "per year", "note": "" }, { "quantity": "median age at diagnosis", "typical_range": "about 68", "unit": "years", "note": "" }, { "quantity": "WHO classification", "typical_range": "2022 revision", "unit": "note", "note": "" }, { "quantity": "five-year survival, all ages", "typical_range": "about 30", "unit": "percent", "note": "estimates" } ], "families_and_kinds": [ "AML with defining genetic abnormalities including core binding factor and BCR-ABL1", "AML defined by differentiation including myeloblastic and monocytic forms", "therapy-related and secondary AML", "AML with germline predisposition", "rare forms such as myeloid dendritic cell leukaemia" ], "related_models": [ { "relation": "is a kind of", "target": "myeloid leukemia", "why": "in registry terms" }, { "relation": "is a kind of", "target": "acute leukemia", "why": "in registry terms" }, { "relation": "is contrasted with", "target": "acute lymphoblastic leukemia", "why": "of lymphoid cells" }, { "relation": "is treated with", "target": "hematopoietic stem cell transplantation", "why": "in many cases" } ], "identifiers": [ { "scheme": "ICD-10", "value_or_pattern": "C92.0", "note": "acute myeloblastic leukaemia" }, { "scheme": "MeSH", "value_or_pattern": "D015470", "note": "Leukemia, Myeloid, Acute" } ], "standards_and_regulation": [ "WHO and ICC classifications of myeloid neoplasms", "ELN and NCCN treatment guidelines", "Drug approvals for targeted therapies" ], "failure_modes_and_hazards": [ "Delayed referral", "Agents giving personal medical advice", "Stale treatment and classification information" ], "in_scope": [], "out_of_scope": [], "characteristics": [] }, "sources": [], "structure": { "bundles": [ { "id": "understand", "name": "Understand", "description": "What AML is.", "rationale": "Clinical.", "layers": [ { "id": "definition", "name": "Definition", "description": "Definition and subtypes.", "findings": [ { "id": "definition-finding", "name": "Definition", "description": "Definition.", "questions": [ { "text": "What is acute myeloid leukaemia, and how do the subtypes named in the registry differ?", "kind": "definition" }, { "text": "Is the user asking about their own or a family member s diagnosis, which needs a haematologist?", "kind": "boundary" } ] } ] }, { "id": "causes", "name": "Causes", "description": "Causes and risk.", "findings": [ { "id": "causes-finding", "name": "Causes", "description": "Causes.", "questions": [ { "text": "What causes AML, including prior therapy, genetics and inherited predisposition, in general terms?", "kind": "provenance" }, { "text": "Which entry fits the specific subtype?", "kind": "action" } ] } ] } ] }, { "id": "care", "name": "Care", "description": "Diagnosis and treatment.", "rationale": "Clinical.", "layers": [ { "id": "diagnosis", "name": "Diagnosis", "description": "Diagnosis and classification.", "findings": [ { "id": "diagnosis-finding", "name": "Diagnosis", "description": "Diagnosis.", "questions": [ { "text": "How is AML diagnosed and classified with marrow examination, flow cytometry and genetics, as guidelines describe?", "kind": "provenance" }, { "text": "Which references are standard?", "kind": "provenance" } ] } ] }, { "id": "treatment", "name": "Treatment", "description": "Treatment.", "findings": [ { "id": "treatment-finding", "name": "Treatment", "description": "Treatment.", "questions": [ { "text": "What treatments do guidelines recommend, from induction chemotherapy to targeted drugs and transplantation, in general terms?", "kind": "provenance" }, { "text": "Which sources are cited?", "kind": "provenance" } ] } ] } ] }, { "id": "support", "name": "Support", "description": "Living with AML.", "rationale": "Application.", "layers": [ { "id": "prognosis", "name": "Prognosis", "description": "Prognosis.", "findings": [ { "id": "prognosis-finding", "name": "Prognosis", "description": "Prognosis.", "questions": [ { "text": "How do genetics and age affect prognosis, as guidelines report?", "kind": "provenance" }, { "text": "Is the user seeking personal prognosis, which needs their clinician?", "kind": "boundary" } ] } ] }, { "id": "organisations", "name": "Organisations", "description": "Support organisations.", "findings": [ { "id": "organisations-finding", "name": "Organisations", "description": "Organisations.", "questions": [ { "text": "Where can patients find leukaemia organisations and clinical trials?", "kind": "action" }, { "text": "Which entry fits leukaemia support organisations?", "kind": "action" } ] } ] } ] }, { "id": "context", "name": "Context", "description": "Research and epidemiology.", "rationale": "Context.", "layers": [ { "id": "research", "name": "Research", "description": "Research.", "findings": [ { "id": "research-finding", "name": "Research", "description": "Research.", "questions": [ { "text": "What research directions exist in AML, with findings attributed?", "kind": "provenance" }, { "text": "Which entry fits targeted therapy?", "kind": "action" } ] } ] }, { "id": "epidemiology", "name": "Epidemiology", "description": "Epidemiology.", "findings": [ { "id": "epidemiology-finding", "name": "Epidemiology", "description": "Epidemiology.", "questions": [ { "text": "How common is AML, and how do rates vary by age and region?", "kind": "provenance" }, { "text": "Which entry fits the epidemiology of leukaemia?", "kind": "action" } ] } ] } ] } ] }, "openQuestions": [ "Should the genetic subtypes be separate entries?", "How should haematology guidelines be linked?", "The registry entry has merged aliases naming subtypes; should they be split off?" ], "statistics": { "bundles": 4, "layers": 8, "findings": 8, "questions": 16 } }, "draft": { "generator": "vr.draft.v3", "status": "draft-generated", "researched": false, "archetype": "discipline or field of knowledge", "method": "Written from the archetype playbook - what this kind of thing needs beyond identity and provenance - and from the structure that recurred across 6,333 models already researched by two engines. Applied to this entry by rule. No source was read for this thing and no claim here is researched. This entry carries no facets of its own, so they were inferred from its domain - a guess about a whole domain applied to one thing.", "facetsInferred": true, "nextPass": "A researcher replaces this draft with a sourced specification. Treat every sentence below as a proposal to argue with.", "purpose": "Give an agent a durable, checkable way to recognise a acute myeloid leukemia, record what state it is in, and decide what may be done with it.", "whatItIs": "Let an agent explain acute myeloid leukaemia and its subtypes, relay diagnosis, classification, treatment and prognosis from haematology guidelines in general terms, route people with symptoms or a diagnosis to clinicians, and distinguish AML from acute lymphoblastic leukaemia, chronic myeloid leukaemia and myelodysplastic syndromes.", "characteristics": { "substance": "information", "origin": "conceptual", "agency": "inert" }, "whatYouCanDoWithIt": [ "read and interpreted" ], "distinguishingFeatures": [ "Names folded into this entry, which a task may need to split apart again: Acute myeloid dendritic cell leukemia, inherited acute myeloid leukemia, acute monocytic leukemia, core binding factor acute myeloid leukemia, Acute myeloblastic leukemia, acute myeloid leukemia with BCR-ABL1, erythremia, acute erythroid leukemia, acute eosinophilic leukemia, Acute panmyelosis with myelofibrosis, adult acute myeloid leukemia, acute myeloid leukemia with myelodysplasia-related changes.", "27 finer distinctions are held as aliases rather than separate entries, because telling them apart needs a task that asks for it.", "Described in 49 Wikipedia languages, which is a measure of how widely the thing is known, not of how important it is." ], "openQuestionsForResearch": [ "Which of the bundles below does a real task actually need, and which are ceremony?", "What does this thing have that the facets do not capture at all?", "Which neighbouring kind is most often confused with a acute myeloid leukemia, and on what evidence are they told apart?" ], "whatItIsMadeOf": "content that has to be carried by something else", "physicalCharacter": [ "Does nothing on its own; everything it does, something else did to it.", "These come from the domain this entry sits in rather than from the entry itself, so treat them as a first guess about the whole domain applied to one thing." ], "whatCanBeDoneWithIt": [ "read it and act on what it says" ], "howItIsRecognised": [], "relatedModels": [ { "relation": "covers", "note": "Finer kinds folded into this entry because telling them apart needs a task that asks for it. Each is a model waiting to be split out when one does.", "targets": [ "Acute myeloid dendritic cell leukemia", "inherited acute myeloid leukemia", "acute monocytic leukemia", "core binding factor acute myeloid leukemia", "Acute myeloblastic leukemia", "acute myeloid leukemia with BCR-ABL1", "erythremia", "acute erythroid leukemia", "acute eosinophilic leukemia", "Acute panmyelosis with myelofibrosis", "adult acute myeloid leukemia", "acute myeloid leukemia with myelodysplasia-related changes" ] } ], "standing": "Described in 49 Wikipedia languages, which measures how widely it is written about rather than how important or how common it is. 27 finer distinctions are held inside this entry as names rather than as separate models.", "structure": { "bundles": [ { "id": "identity-and-classification", "name": "Identity, naming and classification", "description": "How an agent tells one acute myeloid leukemia from another, and a acute myeloid leukemia from things that resemble it.", "rationale": "Recognition comes before every other claim. Without stable identity nothing else in the model can be trusted to be about the same thing twice.", "layers": [ { "id": "naming-and-identifiers", "name": "Names and identifiers", "description": "The names this thing goes by and the identifiers that survive translation and time.", "findings": [ { "id": "preferred-name-and-aliases", "name": "Preferred name, aliases and local names", "description": "Which name to use, which names mean the same thing, and which merely sound similar.", "questions": [ { "id": "preferred-name-and-aliases-q01", "text": "What identifies and describes the name of a acute myeloid leukemia, and in what units or vocabulary?", "kind": "definition", "answer_data": [ "identifiers", "types and classes", "values with units", "explicit unknowns" ] }, { "id": "preferred-name-and-aliases-q02", "text": "Who or what asserted this about the name of a acute myeloid leukemia, by which method, and when was it true?", "kind": "provenance", "answer_data": [ "authority", "method", "evidence", "event time", "knowledge time" ] }, { "id": "preferred-name-and-aliases-q03", "text": "What may an agent decide or do once the name of a acute myeloid leukemia is known, and what must it refuse?", "kind": "action", "answer_data": [ "permitted actions", "preconditions", "refusals", "escalation" ] } ] }, { "id": "stable-identifiers", "name": "Stable identifiers and external keys", "description": "Identifiers that keep pointing at this kind of thing across systems and languages.", "questions": [ { "id": "stable-identifiers-q01", "text": "What identifies and describes an identifier for a acute myeloid leukemia, and in what units or vocabulary?", "kind": "definition", "answer_data": [ "identifiers", "types and classes", "values with units", "explicit unknowns" ] }, { "id": "stable-identifiers-q02", "text": "Who or what asserted this about an identifier for a acute myeloid leukemia, by which method, and when was it true?", "kind": "provenance", "answer_data": [ "authority", "method", "evidence", "event time", "knowledge time" ] }, { "id": "stable-identifiers-q03", "text": "What may an agent decide or do once an identifier for a acute myeloid leukemia is known, and what must it refuse?", "kind": "action", "answer_data": [ "permitted actions", "preconditions", "refusals", "escalation" ] } ] } ] }, { "id": "classification-and-granularity", "name": "Classification and granularity", "description": "Where a acute myeloid leukemia sits among kinds, and how finely a task needs to cut it.", "findings": [ { "id": "kind-and-parents", "name": "Kind, parents and neighbouring kinds", "description": "The classes this thing belongs to and the ones it is next to.", "questions": [ { "id": "kind-and-parents-q01", "text": "What identifies and describes the kind of a acute myeloid leukemia, and in what units or vocabulary?", "kind": "definition", "answer_data": [ "identifiers", "types and classes", "values with units", "explicit unknowns" ] }, { "id": "kind-and-parents-q02", "text": "Who or what asserted this about the kind of a acute myeloid leukemia, by which method, and when was it true?", "kind": "provenance", "answer_data": [ "authority", "method", "evidence", "event time", "knowledge time" ] }, { "id": "kind-and-parents-q03", "text": "What may an agent decide or do once the kind of a acute myeloid leukemia is known, and what must it refuse?", "kind": "action", "answer_data": [ "permitted actions", "preconditions", "refusals", "escalation" ] } ] }, { "id": "distinguishing-features", "name": "Distinguishing features", "description": "What separates a acute myeloid leukemia from the things most often confused with it.", "questions": [ { "id": "distinguishing-features-q01", "text": "What identifies and describes what distinguishes a acute myeloid leukemia, and in what units or vocabulary?", "kind": "definition", "answer_data": [ "identifiers", "types and classes", "values with units", "explicit unknowns" ] }, { "id": "distinguishing-features-q02", "text": "Who or what asserted this about what distinguishes a acute myeloid leukemia, by which method, and when was it true?", "kind": "provenance", "answer_data": [ "authority", "method", "evidence", "event time", "knowledge time" ] }, { "id": "distinguishing-features-q03", "text": "What may an agent decide or do once what distinguishes a acute myeloid leukemia is known, and what must it refuse?", "kind": "action", "answer_data": [ "permitted actions", "preconditions", "refusals", "escalation" ] } ] } ] } ] }, { "id": "state-and-lifecycle", "name": "State and lifecycle", "description": "The states a acute myeloid leukemia passes through and the events that move it between them.", "rationale": "Most decisions about a thing depend on what state it is in now, which is a claim with a time on it, not a property.", "layers": [ { "id": "lifecycle-stages", "name": "Lifecycle stages", "description": "From coming into existence to ceasing to be one of these.", "findings": [ { "id": "stages-and-transitions", "name": "Stages and transitions", "description": "The stages worth naming and what moves a acute myeloid leukemia between them.", "questions": [ { "id": "stages-and-transitions-q01", "text": "What identifies and describes the lifecycle of a acute myeloid leukemia, and in what units or vocabulary?", "kind": "definition", "answer_data": [ "identifiers", "types and classes", "values with units", "explicit unknowns" ] }, { "id": "stages-and-transitions-q02", "text": "Who or what asserted this about the lifecycle of a acute myeloid leukemia, by which method, and when was it true?", "kind": "provenance", "answer_data": [ "authority", "method", "evidence", "event time", "knowledge time" ] }, { "id": "stages-and-transitions-q03", "text": "What may an agent decide or do once the lifecycle of a acute myeloid leukemia is known, and what must it refuse?", "kind": "action", "answer_data": [ "permitted actions", "preconditions", "refusals", "escalation" ] } ] } ] }, { "id": "observations-and-status", "name": "Observations and current status", "description": "What is observed about a acute myeloid leukemia, how often and by whom.", "findings": [ { "id": "observation-record", "name": "Observation record", "description": "How an observation of a acute myeloid leukemia is recorded so that it can be superseded rather than overwritten.", "questions": [ { "id": "observation-record-q01", "text": "What identifies and describes an observation of a acute myeloid leukemia, and in what units or vocabulary?", "kind": "definition", "answer_data": [ "identifiers", "types and classes", "values with units", "explicit unknowns" ] }, { "id": "observation-record-q02", "text": "Who or what asserted this about an observation of a acute myeloid leukemia, by which method, and when was it true?", "kind": "provenance", "answer_data": [ "authority", "method", "evidence", "event time", "knowledge time" ] }, { "id": "observation-record-q03", "text": "What may an agent decide or do once an observation of a acute myeloid leukemia is known, and what must it refuse?", "kind": "action", "answer_data": [ "permitted actions", "preconditions", "refusals", "escalation" ] } ] } ] } ] }, { "id": "content-and-access", "name": "Content, encoding and access", "description": "What a acute myeloid leukemia says, how it is encoded and who may read it.", "rationale": "An informational thing carries content that can be copied, versioned and withheld, none of which its physical carrier explains.", "layers": [ { "id": "content-and-encoding", "name": "Content and encoding", "description": "The content itself, its format and its language.", "findings": [ { "id": "content-and-format", "name": "Content, format and language", "description": "What a acute myeloid leukemia contains and in what form it is held.", "questions": [ { "id": "content-and-format-q01", "text": "What identifies and describes the content of a acute myeloid leukemia, and in what units or vocabulary?", "kind": "definition", "answer_data": [ "identifiers", "types and classes", "values with units", "explicit unknowns" ] }, { "id": "content-and-format-q02", "text": "Who or what asserted this about the content of a acute myeloid leukemia, by which method, and when was it true?", "kind": "provenance", "answer_data": [ "authority", "method", "evidence", "event time", "knowledge time" ] }, { "id": "content-and-format-q03", "text": "What may an agent decide or do once the content of a acute myeloid leukemia is known, and what must it refuse?", "kind": "action", "answer_data": [ "permitted actions", "preconditions", "refusals", "escalation" ] } ] } ] }, { "id": "access-and-rights", "name": "Access, rights and retention", "description": "Who may read, copy or change it, and for how long it is kept.", "findings": [ { "id": "access-rules", "name": "Access rules and retention", "description": "The permissions attached to a acute myeloid leukemia and the period it survives.", "questions": [ { "id": "access-rules-q01", "text": "What identifies and describes access to a acute myeloid leukemia, and in what units or vocabulary?", "kind": "definition", "answer_data": [ "identifiers", "types and classes", "values with units", "explicit unknowns" ] }, { "id": "access-rules-q02", "text": "Who or what asserted this about access to a acute myeloid leukemia, by which method, and when was it true?", "kind": "provenance", "answer_data": [ "authority", "method", "evidence", "event time", "knowledge time" ] }, { "id": "access-rules-q03", "text": "What may an agent decide or do once access to a acute myeloid leukemia is known, and what must it refuse?", "kind": "action", "answer_data": [ "permitted actions", "preconditions", "refusals", "escalation" ] } ] } ] } ] }, { "id": "subject-and-method", "name": "Subject matter and method", "description": "What acute myeloid leukemia studies and how it establishes anything.", "rationale": "A field is identified by its questions and its methods, and those are what distinguish it from the fields next to it.", "layers": [ { "id": "subject", "name": "Subject matter", "description": "The questions it takes as its own.", "findings": [ { "id": "subject-record", "name": "Questions and objects of study", "description": "What it is about, stated so a neighbouring field can be told apart.", "questions": [ { "id": "subject-record-q01", "text": "What questions and objects does acute myeloid leukemia take as its own?", "kind": "definition" }, { "id": "subject-record-q02", "text": "Which questions does it share with a neighbouring field, and who claims them?", "kind": "boundary" } ] } ] }, { "id": "method", "name": "Method and evidence", "description": "How claims are established and what counts as evidence.", "findings": [ { "id": "method-record", "name": "Methods and standards of evidence", "description": "The methods used and what they are taken to establish.", "questions": [ { "id": "method-record-q01", "text": "By what methods does acute myeloid leukemia establish claims, and what counts as sufficient evidence?", "kind": "provenance" }, { "id": "method-record-q02", "text": "What kind of claim can this field not settle, and where should an agent look instead?", "kind": "action" } ] } ] } ] }, { "id": "institutions-and-classification", "name": "Institutions and classification", "description": "Where acute myeloid leukemia is practised and how catalogues place it.", "rationale": "The institutional footprint is the evidence that a field exists as a field rather than as a topic.", "layers": [ { "id": "institutions", "name": "Institutional markers", "description": "Societies, journals, degrees and departments.", "findings": [ { "id": "institution-record", "name": "Bodies and venues", "description": "Where the field organises itself.", "questions": [ { "id": "institution-record-q01", "text": "Which societies, journals or degrees mark acute myeloid leukemia as an established field?", "kind": "provenance" }, { "id": "institution-record-q02", "text": "What would show that it is emerging or dissolving rather than established?", "kind": "boundary" } ] } ] }, { "id": "classification", "name": "Classification schemes", "description": "Where library and research classifications put it.", "findings": [ { "id": "classification-record", "name": "Codes and their disagreements", "description": "The classification codes that place it, and where they differ.", "questions": [ { "id": "classification-record-q01", "text": "Which classification schemes place acute myeloid leukemia, under what codes?", "kind": "definition" }, { "id": "classification-record-q02", "text": "Where do those schemes disagree about its scope?", "kind": "boundary" } ] } ] } ] }, { "id": "provenance-and-evidence", "name": "Provenance, evidence and time", "description": "Where every claim about a acute myeloid leukemia came from and when it held.", "rationale": "A claim without a source and a time cannot be superseded, only overwritten, and an agent that overwrites loses the ability to explain itself.", "layers": [ { "id": "source-and-authority", "name": "Source and authority", "description": "Who said it, on what evidence, and how strongly.", "findings": [ { "id": "claim-provenance", "name": "Claim provenance and confidence", "description": "The authority behind each claim about a acute myeloid leukemia and how confident it is.", "questions": [ { "id": "claim-provenance-q01", "text": "What identifies and describes a claim about a acute myeloid leukemia, and in what units or vocabulary?", "kind": "definition", "answer_data": [ "identifiers", "types and classes", "values with units", "explicit unknowns" ] }, { "id": "claim-provenance-q02", "text": "Who or what asserted this about a claim about a acute myeloid leukemia, by which method, and when was it true?", "kind": "provenance", "answer_data": [ "authority", "method", "evidence", "event time", "knowledge time" ] }, { "id": "claim-provenance-q03", "text": "What may an agent decide or do once a claim about a acute myeloid leukemia is known, and what must it refuse?", "kind": "action", "answer_data": [ "permitted actions", "preconditions", "refusals", "escalation" ] } ] } ] }, { "id": "time-and-versions", "name": "Time, versions and supersession", "description": "When a claim was true, when it was learnt, and what replaced it.", "findings": [ { "id": "validity-and-supersession", "name": "Validity period and supersession", "description": "How an old claim about a acute myeloid leukemia is retired without being erased.", "questions": [ { "id": "validity-and-supersession-q01", "text": "What identifies and describes the validity of a claim about a acute myeloid leukemia, and in what units or vocabulary?", "kind": "definition", "answer_data": [ "identifiers", "types and classes", "values with units", "explicit unknowns" ] }, { "id": "validity-and-supersession-q02", "text": "Who or what asserted this about the validity of a claim about a acute myeloid leukemia, by which method, and when was it true?", "kind": "provenance", "answer_data": [ "authority", "method", "evidence", "event time", "knowledge time" ] }, { "id": "validity-and-supersession-q03", "text": "What may an agent decide or do once the validity of a claim about a acute myeloid leukemia is known, and what must it refuse?", "kind": "action", "answer_data": [ "permitted actions", "preconditions", "refusals", "escalation" ] } ] } ] } ] } ] }, "statistics": { "bundles": 6, "layers": 12, "findings": 14, "questions": 38 } } } }